parkinson plus syndrome
Jump to navigation
Jump to search
Introduction
Differentiated from Parkinson's disease by the presence of additional signs & symptoms.
Clinical manifestations
- often more rapidly progressive than Parkinson's disease
Laboratory
* also see Parkinson's disease
Differential diagnosis
Distinguishing features of Parkinson's disease (PD), progressive supranuclear palsy (PSP) & Shy-Drager Syndrome:
| sign/symptom | PD | PSP | Shy-Drager |
|---|---|---|---|
| bradykinesia | 3+ | 3+ | 3+ |
| rigidity | 3+ | 3+ | 3+ |
| tremor | 3+ | 1+ | 1+ |
| autonomic dysfunction | 2+ | 1+ | 4+ |
| pyramidal signs | 0 | 1+ | 0 |
| cerebellar signs | 0 | 1+ | 2+ |
| supranuclear gaze palsy | 0 | 3+ | 0 |
| response to Sinemet | + | - | - |
* PSP: progressive supranuclear palsy
* PD: Parkinson's disease
Management
More general terms
More specific terms
- amyotrophic lateral sclerosis-parkinsonism-dementia complex of Guam
- cortical-basal ganglionic degeneration; corticobasal degeneration
- disinhibition-dementia-parkinsonism-amyotrophy complex (DDPAC)
- frontotemporal dementia with parkinsonism (FTDP-17); multiple system tauopathy with presenile dementia (MSTD)
- multiple system atrophy (MSA)
- pallidopontonigral degeneration
- progressive supranuclear palsy; Steele-Richardson-Olszewski syndrome (PSP)
References
- ↑ Saunders Manual of Medical Practice, Rakel (ed), WB Saunders, Philadelphia, 1996, pg 1051
- ↑ 2.0 2.1 2.2 Medical Knowledge Self Assessment Program (MKSAP) 11, 16, 17, 18, 19. American College of Physicians, Philadelphia 1998, 2012, 2015, 2018, 2021
- ↑ 3.0 3.1 Pereira JB, Kumar A, Hall S et al DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease. Nat Aging 2023. Sept 18 PMID: https://www.ncbi.nlm.nih.gov/pubmed/37723208 https://www.nature.com/articles/s43587-023-00478-y